Name: 글로벌 시장 동향
SKU: PH7227
Availability: InStock

보고서 요약(국문)

개요
전 세계 비알코올성 지방간 질환(NAFLD) 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.

비알코올성 지방간 질환(NAFLD)은 간에 지방이 축적되어 발생하는 다양한 질환을 통칭하는 용어입니다. 일반적으로 과체중 또는 비만인 사람에게서 나타납니다. 건강한 간에는 지방이 거의 또는 전혀 없어야 합니다. 영국에서는 약 3명 중 1명이 간에 소량의 지방이 존재하는 초기 단계의 NAFLD를 앓고 있는 것으로 추정됩니다. 초기 단계의 NAFLD는 일반적으로 해롭지 않지만, 악화될 경우 간경변을 포함한 심각한 간 손상으로 이어질 수 있습니다.

현재 인슐린 민감제(티아졸리딘디온)와 항산화제(비타민 E)는 비알코올성 지방간 질환(NAFLD)/비알코올성 지방간염(NASH) 치료에 매우 효과적인 치료제로 여겨지며, 지질 저하제, 인슐린 민감제, 안지오텐신 수용체 차단제, n-3 다중불포화지방산 또한 치료에 사용되고 있습니다.
시장 동향: 성장 동인 및 제약 요인
높은 유병률
비알코올성 지방간 질환(NAFLD)의 높은 유병률은 예측 기간 동안 세계 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 미국 국립 당뇨병·소화기·신장질환연구소(NIDDK)에 따르면 NAFLD는 비만 및 제2형 당뇨병을 포함한 비만 관련 질환을 가진 사람들에게서 매우 흔하게 나타납니다. 연구에 따르면 제2형 당뇨병 환자의 3분의 1에서 3분의 2가 NAFLD를 가지고 있습니다. 연구에 따르면 과체중인 사람의 약 75%, 고도비만인 사람의 90% 이상에서 비알코올성 지방간 질환(NAFLD)이 나타나는 것으로 밝혀졌습니다.
또한 미국 간 재단(American Liver Foundation)에 따르면 미국에서 약 1억 명이 비알코올성 지방간 질환을 앓고 있는 것으로 추정됩니다. 비알코올성 지방간 질환(NAFLD)은 소아에서 가장 흔한 간 질환이며 지난 20년 동안 두 배로 증가했습니다.
엄격한 규제 당국
신약 치료제 승인에 대한 엄격한 규제 당국의 요구는 세계 시장 성장을 저해할 것으로 예상됩니다. 또한 높은 신약 개발 비용과 치료 부작용 역시 예측 기간 동안 세계 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
세계 비알코올성 지방간 질환(NAFLD) 시장은 약물 종류, 질병 단계, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.

비알코올성 지방간 질환(NAFLD) 중 비알코올성 지방간염(NASH) 단계 치료제가 시장을 주도할 것으로 예상됩니다.
미국 식품의약국(FDA)의 연구 승인이 증가함에 따라, NAFLD 중 비알코올성 지방간염(NASH) 단계 치료제가 예측 기간 동안 세계 시장을 주도할 것으로 전망됩니다. 예를 들어, 2023년 9월, 비알코올성 지방간염(NASH) 치료를 위한 신약 개발을 진행 중인 임상 단계 바이오제약 회사인 마드리갈 파마슈티컬스(Madrigal Pharmaceuticals, Inc.)는 간 섬유증을 동반한 성인 NASH 환자 치료를 위한 레스메트린(resmethrin)에 대해 FDA 신약 허가 신청(NDA) 승인을 받았습니다.
또한, 2023년 6월, 머크(Merck)는 한국 제약회사 한미약품으로부터 기술을 이전받은 에피노페그두티드(Efinopegdutide)에 대해 미국 FDA로부터 신속심사 지정을 받았습니다. 마찬가지로, 2022년 5월 화이자(Pfizer Inc.)는 비알코올성 지방간염(NASH) 및 간 섬유증 치료를 위한 임상 단계 복합 요법에 대해 미국 식품의약국(FDA)의 신속 심사(Fast Track) 지정을 획득했습니다.
지역 분석
북미, 세계 시장 주도 예상
북미 지역의 연구 자금 및 투자 증가로 인해 해당 지역 시장 성장이 촉진되어 예측 기간 동안 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 심혈대사 건강 증진에 주력하는 임상 단계 바이오제약 회사인 리버스 파마슈티컬스(Rivus Pharmaceuticals Inc.)는 2022년 9월 RA 캐피털 매니지먼트(RA Capital Management)가 주도하고 베인 캐피털 라이프 사이언스(Bain Capital Life Sciences), BB 바이오테크(BB Biotech AG), 그리고 기존 투자자인 롱튜드 캐피털(Longitude Capital), 메딕시(Medicxi), Rx캐피털(RxCapital)이 참여한 1억 3,200만 달러 규모의 시리즈 B 투자를 유치했습니다. 이번 자금 조달은 심혈관 대사 질환의 직접적인 원인인 비만을 조절하여 심혈관 대사 질환을 치료하기 위해 개발된 최초의 조절 대사 가속기(CMA)인 주요 후보 물질 HU6의 임상 개발을 더욱 뒷받침할 것으로 예상됩니다.
또한, 미국 식품의약국(FDA)에서 승인한 비알코올성 지방간 질환(NAFLD) 치료제가 없는 상황에서, 캘리포니아 대학교 샌디에이고 의과대학의 UC 샌디에이고 NAFLD 연구센터 연구진에게 최근 지원된 957만 달러의 자금은 NAFLD 환자를 위한 새로운 치료법을 연구하는 임상 시험에 도움이 될 것으로 기대됩니다.

COVID-19 영향 분석
코로나19 팬데믹은 플라스미노겐 활성 억제제-1(PAI-1)이 COVID-19 환자에게서 증가하는 것으로 관찰됨에 따라 치료 수요 증가로 이어져 전 세계 시장 성장에 긍정적인 영향을 미쳤을 것으로 추정됩니다. PAI-1 수치는 섬유화 조직에서 현저히 증가하지만, PAI-1 결핍은 손상 관련 섬유화 신호에 반응하여 다른 장기를 섬유화로부터 보호합니다. 따라서 PAI-1은 심장, 폐, 신장, 간, 피부를 포함한 다양한 장기의 섬유화 병리에 관여합니다. 특히 비알코올성 지방간 질환(NAFLD) 환자에게 있어 PAI-1이 COVID-19로 인한 간 손상에 미치는 역할은 매우 흥미로운데, PAI-1 수치 상승이 NAFLD 및 비알코올성 지방간염(NASH)과 관련이 있는 것으로 알려져 있기 때문에 COVID-19로 인한 PAI-1 수치 상승이 NAFLD를 악화시킬 수 있다는 것입니다.

시장 세분화
약물 종류별
• 항산화제
• 지질 저하제
• 인슐린 민감제
• 펜톡시필린
• 안지오텐신 수용체 차단제
• 기타
질병 단계별
• 비알코올성 지방간염(NASH)
• 간경변증
• 간 섬유증
투여 경로별
• 주사제
• 경구제
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발
• 2022년 4월, 오라메드 파마슈티컬스(Oramed Pharmaceuticals) 주식회사(Inc.)는 유럽 특허청으로부터 "비알코올성 지방간 질환(NAFLD), 지방간 및 그 후유증 치료 방법 및 조성물"이라는 특허를 취득했습니다. 이 회사는 소화계에서 치료용 단백질을 보호하는 경구 단백질 전달 플랫폼 기술을 개발했습니다.
• 2023년 3월, 심각한 대사 장애와 높은 미충족 의료 수요를 가진 환자를 위한 혁신적인 치료법을 개발하는 임상 단계 기업인 아케로 테라퓨틱스(Akero Therapeutics, Inc.)는 미국 식품의약국(FDA)과의 2상 종료 회의에서 긍정적인 결과를 발표했으며, 비알코올성 지방간염(NASH) 치료를 위한 에프룩시페르민의 SYNCHRONY 3상 임상시험 일정에 대한 세부 정보를 공개했습니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Pfizer Inc., AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., Abbvie Inc., Gilead Sciences, Inc. 등이 있습니다.
보고서 구매 이유

• 약물 종류, 질병 단계, 투여 경로, 유통 채널 및 지역별 글로벌 비알코올성 지방간 질환(NAFLD) 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 비알코올성 지방간 질환(NAFLD) 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 비알코올성 지방간 질환(NAFLD) 시장 보고서는 약 64개의 표, 61개의 그림, 그리고 186페이지 분량으로 구성될 예정입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Nonalcoholic Fatty Liver Disease (NAFLD) market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Non-alcoholic fatty liver disease (NAFLD) is the term for a spectrum of conditions caused by a build-up of fat in the liver. It's usually seen in people who are overweight or obese. A healthy liver should contain little or no fat. It is assessed that nearly 1 in out of 3 individuals in the UK has premature phases of NAFLD where there exist little quantities of fat in their liver. Early-stage NAFLD does not usually induce any harm, but it can direct to severe liver damage, including cirrhosis if it gets worse.
Presently, insulin sensitizers (thiazolidinediones) and antioxidants (vitamin E) appear to be the highly advantageous therapeutic agents for NAFLD/NASH, and lipid-lowering drugs, Insulin sensitizers, angiotensin receptor blockers, and n-3 polyunsaturated fatty acids also have been employed in the treatment.
Market Dynamics: Drivers & Restraints
High Prevalence of Condition
The high prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) is expected to boost the global market growth during the forecast period. For instance, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NAFLD is highly typical in individuals who have certain diseases and disorders, such as obesity, and conditions that may be linked to obesity, including type 2 diabetes. Investigations indicate that one-third to two-thirds of individuals with type 2 diabetes have NAFLD. Research also indicates that NAFLD is present in around 75% of individuals who are overweight and in over 90% of individuals who have severe obesity.
Moreover, according to the American Liver Foundation, approximately 100 million people in the United States are assessed to have nonalcoholic fatty liver disease. Nonalcoholic Fatty Liver Disease (NAFLD), is the most typical condition of liver disorder in children and has increased two folds over the past 20 years.
Stringent Regulatory Authorities
The stringent regulatory authorities authorizing the new drug treatments are expected to hamper the global market growth. Furthermore, high drug development costs and treatment side effects are also expected to hamper the global market growth in the forecast period.
Segment Analysis
The global Nonalcoholic Fatty Liver Disease (NAFLD) market is segmented based on drug class, disease stage, route of administration, distribution channel and region.
Non-Alcoholic Steatohepatitis (NASH) Stage of NAFLD is Expected to Dominate Market
Owing to the increasing research approval from the FDA the Non-Alcoholic Steatohepatitis (NASH) Stage of NAFLD is expected to dominate the global market during the forecast period. For instance, in September 2023 Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical corporation pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), obtained the U.S. Food and Drug Administration (FDA) New Drug Application (NDA) award for resmethrin to treat adult patients with NASH with liver fibrosis.
Moreover, in June 2023, Merck, obtained Fast Track Designation from the U.S. Food and Drug for Efinopegdutide, a technology transferred from the South Korean pharmaceutical corporation Hanmi Pharmaceutical Co., to treat nonalcoholic steatohepatitis (NASH). Similarly, in May 2022, Pfizer Inc. acquired the U.S. Food and Drug Administration (FDA) Fast Track designation for its investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.
Geographical Analysis
North America is Expected to Dominate the Global Market
The increasing research funding and investments in North America are expected to boost the regional market growth, thereby dominating the global market in the forecast period. For instance, in September 2022, Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical corporation committed to enhancing cardio-metabolic health, secured a $132 million Series B financing conducted by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital. This financing is expected to additionally sustain the clinical advance of principal nominee HU6, a first-in-class Controlled Metabolic Accelerator (CMA) developed for the treatment of cardio-metabolic disorder by managing obesity, a direct driver of disorder.
Moreover, since there are no medications authorized by the U.S. Food and Drug Administration (FDA) for the treatment of NAFLD. A recent $9.57 million funding granted to researchers with the UC San Diego NAFLD Research Center at the University of California San Diego School of Medicine is expected to aid in the clinical trial to investigate new threatment choices for individuals with the condition.
COVID-19 Impact Analysis
The pandemic is estimated to have positively impacted the global market growth owing to an increase in treatment demand as Plasminogen activator inhibitor-1 is observed to be advanced in COVID-19 patients. While the level of PAI-1 is significantly elevated in fibrotic tissues, the lack of PAI-1 protects different organs from fibrosis in response to injury-related profibrotic signals.
Thus, PAI-1 is implicated in the pathology of fibrosis in different organs including the heart, lung, kidney, liver, and skin. This role of PAI-1 in COVID-19 liver injury is potentially interesting, especially in NAFLD patients, as elevated PAI-1 has been associated with NAFLD and NASH therefore, COVID-19-induced PAI-1 elevation aggravated NAFLD.
Market Segmentation
By Drug Class
• Antioxidants
• Lipid-Lowering Drugs
• Insulin sensitizers
• Pentoxifylline
• Angiotensin receptor blockers
• Others
By Disease Stage
• Non-Alcoholic Steatohepatitis (NASH)
• Cirrhosis
• Fibrosis
By Route of Administration
• Injectable
• Oral
• Other
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In April 2022, Oramed Pharmaceuticals Inc. acquired the patent termed “Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof” from the European Patent Office. They have produced oral protein delivery platform technology which protects therapeutic proteins in the digestive system.
• In March 2023 Akero Therapeutics, Inc., a clinical-stage corporation designing transformational therapies for patients with serious metabolic disorders and high unmet medical needs, declared positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and details of the anticipated SYNCHRONY Phase 3 efruxifermin schedule for the treatment of nonalcoholic steatohepatitis (NASH).
Competitive Landscape
The major global players in the market include Pfizer Inc., AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc., F. Hoffmann-La Roche Ag, Merck & Co., Inc., Abbvie Inc., And Gilead Sciences, Inc. among others.
Why Purchase the Report?
• To visualize the global Nonalcoholic Fatty Liver Disease (NAFLD) market segmentation based on drug class, disease stage, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Nonalcoholic Fatty Liver Disease (NAFLD) market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global Nonalcoholic Fatty Liver Disease (NAFLD) market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Disease Stage
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. High Prevalence of Condition
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. Pipeline Analysis
5.8. Epidemiology
5.9. SWOT Analysis
5.10. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Antioxidants*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Lipid-Lowering Drugs
7.4. Insulin sensitizers
7.5. Pentoxifylline
7.6. Angiotensin Receptor Blockers
7.7. Others
8. By Disease Stage
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
8.1.2. Market Attractiveness Index, By Disease Stage
8.2. Non-Alcoholic Steatohepatitis (NASH)*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cirrhosis
8.4. Fibrosis
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Injectable*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Oral
9.4. Other
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. AstraZeneca
13.3. Novartis AG
13.4. Takeda Pharmaceutical Company Limited.
13.5. Intercept Pharmaceuticals, Inc.
13.6. F. Hoffmann-La Roche AG
13.7. Merck & Co., Inc.
13.8. AbbVie Inc.
13.9. Gilead Sciences, Inc.
13.10. Akero Therapeutics, Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4.	Key Developments, AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., AbbVie Inc., Gilead Sciences, Inc., Akero Therapeutics, Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Disease Stage, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 7 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Disease Stage, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Disease Stage, 2021-2030 (US$ Million)

Table 9 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 11 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 14 North America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Disease Stage, 2021-2030 (US$ Million)

Table 15 North America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 16 North America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 18 South America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Disease Stage, 2021-2030 (US$ Million)

Table 19 South America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 20 South America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 22 Europe Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Disease Stage, 2021-2030 (US$ Million)

Table 23 Europe Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 24 Europe Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Disease Stage, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Disease Stage, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 32 Pfizer Inc.: Overview

Table 33 Pfizer Inc.: Product Portfolio

Table 34 Pfizer Inc.: Key Developments

Table 35 AstraZeneca: Overview

Table 36 AstraZeneca: Product Portfolio

Table 37 AstraZeneca: Key Developments

Table 38 Novartis AG: Overview

Table 39 Novartis AG: Product Portfolio

Table 40 Novartis AG: Key Developments

Table 41 Takeda Pharmaceutical Company Limited.: Overview

Table 42 Takeda Pharmaceutical Company Limited.: Product Portfolio

Table 43 Takeda Pharmaceutical Company Limited.: Key Developments

Table 44 Intercept Pharmaceuticals, Inc.: Overview

Table 45 Intercept Pharmaceuticals, Inc.: Product Portfolio

Table 46 Intercept Pharmaceuticals, Inc.: Key Developments

Table 47 F. Hoffmann-La Roche AG: Overview

Table 48 F. Hoffmann-La Roche AG: Product Portfolio

Table 49 F. Hoffmann-La Roche AG: Key Developments

Table 50 Merck & Co., Inc.: Overview

Table 51 Merck & Co., Inc.: Product Portfolio

Table 52 Merck & Co., Inc.: Key Developments

Table 53 AbbVie Inc.: Overview

Table 54 AbbVie Inc.: Product Portfolio

Table 55 AbbVie Inc.: Key Developments

Table 56 Gilead Sciences, Inc.: Overview

Table 57 Gilead Sciences, Inc.: Product Portfolio

Table 58 Gilead Sciences, Inc.: Key Developments

Table 59 Akero Therapeutics, Inc.: Overview

Table 60 Akero Therapeutics, Inc.: Product Portfolio

Table 61 Akero Therapeutics, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 2 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Drug Class, 2022 & 2030 (%)

Figure 3 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Disease Stage, 2022 & 2030 (%)

Figure 4 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 7 Antioxidants Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 8 Lipid-Lowering Drugs Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 9 Insulin sensitizers Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 10 Pentoxifylline Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 11 Angiotensin receptor blockers Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 12 Others Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 13 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Y-o-Y Growth, By Disease Stage, 2022-2030 (%)

Figure 14 Non-Alcoholic Steatohepatitis (NASH) Disease Stage in Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 15 Cirrhosis Disease Stage in Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 16 Fibrosis Disease Stage in Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 17 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 18 Injectable Route of Administration in Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 19 Oral Route of Administration in Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 20 Other Route of Administration in Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 21 Others Route of Administration in Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 22 Retail Pharmacies Distribution Channel in Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 23 Online Pharmacies Distribution Channel in Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 24 Others Distribution Channel in Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 25 Global Nonalcoholic Fatty Liver Disease (NAFLD) Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 26 North America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 27 Asia-Pacific Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 28 Europe Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 29 South America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 30 Middle East and Africa Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 31 North America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 32 North America Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Drug Class, 2022 & 2030 (%)

Figure 33 North America Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Disease Stage, 2022 & 2030 (%)

Figure 34 North America Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 35 North America Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Country, 2022 & 2030 (%)

Figure 36 South America Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 37 South America Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Drug Class, 2022 & 2030 (%)

Figure 38 South America Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Disease Stage, 2022 & 2030 (%)

Figure 39 South America Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 40 South America Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Country, 2022 & 2030 (%)

Figure 41 Europe Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 42 Europe Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Drug Class, 2022 & 2030 (%)

Figure 43 Europe Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Disease Stage, 2022 & 2030 (%)

Figure 44 Europe Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 45 Europe Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Country, 2022 & 2030 (%)

Figure 46 Asia-Pacific Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 47 Asia-Pacific Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Drug Class, 2022 & 2030 (%)

Figure 48 Asia-Pacific Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Disease Stage, 2022 & 2030 (%)

Figure 49 Asia-Pacific Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 50 Asia-Pacific Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Country, 2022 & 2030 (%)

Figure 51 Middle East & Africa Nonalcoholic Fatty Liver Disease (NAFLD) Market Value, 2021-2030 (US$ Million)

Figure 52 Middle East & Africa Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Drug Class, 2022 & 2030 (%)

Figure 53 Middle East & Africa Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Disease Stage, 2022 & 2030 (%)

Figure 54 Middle East & Africa Nonalcoholic Fatty Liver Disease (NAFLD) Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 55 Pfizer Inc.: Financials

Figure 56 AstraZeneca: Financials

Figure 57 Novartis AG: Financials

Figure 58 Takeda Pharmaceutical Company Limited.: Financials

Figure 59 Intercept Pharmaceuticals, Inc.: Financials

Figure 60 F. Hoffmann-La Roche AG: Financials

Figure 61 Merck & Co., Inc.: Financials

Figure 62 AbbVie Inc.: Financials

Figure 63 Gilead Sciences, Inc.: Financials

Figure 64 Akero Therapeutics, Inc.: Financials

세계 비알코올성 지방간 질환(NAFLD) 시장 – 2023-2030

Global Nonalcoholic Fatty Liver Disease (NAFLD) Market - 2023-2030